Dong-A ST Co., Ltd. (KRX:170900)

South Korea flag South Korea · Delayed Price · Currency is KRW
51,600
-1,200 (-2.27%)
Last updated: Nov 25, 2025, 9:00 AM KST
-14.70%
Market Cap491.82B
Revenue (ttm)770.63B
Net Income (ttm)-514.77M
Shares Out9.16M
EPS (ttm)-41.77
PE Ration/a
Forward PE23.38
Dividend686.27 (1.33%)
Ex-Dividend DateMar 13, 2025
Volume26,692
Average Volume43,826
Open52,500
Previous Close52,800
Day's Range51,000 - 53,000
52-Week Range40,900 - 62,843
Beta0.48
RSI63.48
Earnings DateOct 30, 2025

About Dong-A ST

Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products in South Korea and internationally. It offers various ethical drugs, including Clofazimine cap. For lepromatous leprosy; Closerin Cap for active pulmonary and extra-pulmonary tuberculosis; Eporon inj./PFS for anemia associated with chronic renal failure; Gemcit inj. to treat non-small cell lung, pancreatic, breast, bladder, and ovarian cancers; Gonadopin inj./PFS for infertility and anovulation; Growtropin II inj./AQ /cartridge to treat growth failure due to an inad... [Read more]

Sector Healthcare
Founded 1932
Employees 1,679
Stock Exchange Korea Stock Exchange
Ticker Symbol 170900
Full Company Profile

Financial Performance

Financial Statements

News

Dong-A ST Secures European Approval for Stelara Biosimilar IMULDOSA

– Global Market Expansion Accelerates with Back-to-Back FDA and EC Authorizations SEOUL, South Korea — Dong-A ST (CEO: Jeong Jae-hoon, KRX: 170900) proudly announces that its Stelara biosimilar, IMULD...

1 year ago - Financial Post

US FDA Approves Dong-A ST’s IMULDOSA™ (ustekinumab-srlf), a Biosimilar to STELARA®

Dong-A ST’s biologics license application (BLA) for Imuldosa, submitted in October 2023, is approved by the U.S. Food and Drug Administration SEOUL, South Korea — Dong-A ST (President/CEO Jae-Hun Jung...

1 year ago - Financial Post

US FDA Approves Dong-A ST's IMULDOSA™ (ustekinumab-srlf), a Biosimilar to STELARA®

Dong-A ST's biologics license application (BLA) for Imuldosa, submitted in October 2023, is approved by the U.S. Food and Drug Administration Dong-A ST (President/CEO Jae-Hun Jung, KRX: 170900) announ...

1 year ago - Benzinga